Engineering Related Topics 
Fierce Pharma
AUGUST 2, 2024
Adaptimmune has won accelerated FDA approval | Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade.
MedCity News
OCTOBER 1, 2024
The post Nym Rakes In $47M for Autonomous Coding Engine appeared first on MedCity News. Autonomous coding startup Nym raised $47 million. The New York City-based company has 21 provider customers, including Geisinger and Ochsner Health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 1, 2023
After wild pandemic ride, is Novavax destined to be the little engine that couldn’t? kdunleavy Wed, 03/01/2023 - 07:10
MedCity News
AUGUST 2, 2024
The post Beyond Engineering: Integrating UX for Safer and More Efficient Medical Products appeared first on MedCity News. While the approach to patient and treatment safety is crucial, there is a notable shift towards processes centered around patients and healthcare professionals.
Advertiser: ZoomInfo
Data is the fuel that powers your ABM engine. The benefits of account-based marketing are clear: internal alignment, shorter sales cycles, higher conversion rates. But none of this is possible without the most important element of a successful ABM program: good data. Without it, you can’t find and reach your target accounts.
MedCity News
AUGUST 2, 2024
It’s the first engineered cell therapy approved for treating a solid tumor. The post Adaptimmune’s FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors appeared first on MedCity News. The FDA approved Adaptimmune Therapeutics’ Tecelra as a treatment for advanced cases of synovial sarcoma.
European Pharmaceutical Review
AUGUST 2, 2024
The post FDA approves innovative engineered cell therapy appeared first on European Pharmaceutical Review. With US approval TECELRA, “there is a renewed sense of hope for this patient community.”
Expert insights. Personalized for you.
330 
Let's personalize your content